Compare FIVN & AMLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FIVN | AMLX |
|---|---|---|
| Founded | 2001 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 2.0B |
| IPO Year | 2014 | 2021 |
| Metric | FIVN | AMLX |
|---|---|---|
| Price | $27.45 | $20.35 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 18 | 9 |
| Target Price | ★ $26.06 | $21.56 |
| AVG Volume (30 Days) | ★ 2.4M | 1.6M |
| Earning Date | 04-30-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 364.71 | 65.46 |
| EPS | ★ 0.21 | N/A |
| Revenue | ★ $1,149,088,000.00 | $380,786,000.00 |
| Revenue This Year | $11.39 | N/A |
| Revenue Next Year | $10.00 | N/A |
| P/E Ratio | $132.40 | ★ N/A |
| Revenue Growth | 10.28 | ★ 1612.94 |
| 52 Week Low | $13.29 | $7.48 |
| 52 Week High | $28.86 | $20.90 |
| Indicator | FIVN | AMLX |
|---|---|---|
| Relative Strength Index (RSI) | 63.52 | 59.66 |
| Support Level | $17.66 | $12.14 |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 1.67 | 1.28 |
| MACD | 0.23 | 0.13 |
| Stochastic Oscillator | 81.91 | 68.10 |
Five9 offers cloud-native contact center software enabling digital customer service, sales, and marketing engagement. The company's Intelligent CX platform combines core telephony functionality, omnichannel engagement, and modules into a cloud contact-center-as-a-service, or CCaaS, platform. Five9's modules include digital self-service, agent assist technology, workflow automation, and optimization solutions, as well as artificial intelligence-driven automation solutions that optimize customer service efficiency and manage interaction quality and agent performance.
Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on developing novel therapies for communities with high unmet medical needs. The company has preclinical and clinical development programs in endocrine conditions and neurodegenerative diseases. Its pipeline includes investigational therapies matched with diseases based on mechanistic rationale, clinical outcomes, biomarkers, and preclinical data. The company is currently developing avexitide for Post-Bariatric Hypoglycemia, AMX0035 for Wolfram Syndrome, AMX0114 for Amyotrophic Lateral Sclerosis, and AMX0318 for Post-Bariatric Hypoglycemia and other rare diseases.